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Abstract
Background: Combined use of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs may
induce acute kidney injury in humans, especially when combined with diuretics. The objective of this investigation was to
evaluate the effects of benazepril, robenacoxib and their combination in healthy cats.
In each of two studies (study 1 followed by study 2), 32 healthy cats were randomised to one of four groups (n = 4 male
and 4 female cats per group) in a parallel-group design. The groups received orally once daily for 7 days either placebo
(control group), benazepril, robenacoxib or benazepril plus robenacoxib. In study 2, all groups received in addition
0.5 mg/kg furosemide twice daily by subcutaneous injection for 7 days.
Results: Benazepril, robenacoxib and their combination were well tolerated as evidenced from lack of clinical signs
and no negative effects on body weight, feed consumption and clinical chemistry, haematology and urinalysis variables.
The primary endpoint of the study was the glomerular filtration rate (GFR), which was estimated from the plasma
clearance of iohexol. In the absence of furosemide, GFR was significantly higher in cats receiving the combination of
benazepril plus robenacoxib compared to the other three groups, and was also significantly higher in females receiving
only benazepril compared to the control.
Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system,
evidenced from increased plasma renin activity and plasma aldosterone concentrations. Compared to the control group
in cats treated with furosemide, GFR was increased by benazepril (females only) but decreased by robenacoxib (males
only). Benazepril, robenacoxib and their combination significantly inhibited the increase in plasma aldosterone induced by
furosemide.
Conclusions: The combination of benazepril and robenacoxib was well tolerated and either increased or had a neutral
effect on GFR in healthy cats without or with concomitant furosemide. The combination of benazepril and robenacoxib
reduced plasma aldosterone concentrations increased by furosemide. It is recommended to test the efficacy and safety of
the combined use of benazepril and robenacoxib in cats with clinical disease, notably proteinuric chronic kidney disease.
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Background
Angiotensin-converting enzyme (ACE) inhibitors (ACEIs)
are used in the management of various diseases in cats,
notably chronic kidney disease (CKD) [1]. Nonsteroidal
anti-inflammatory drugs (NSAIDs) are used to treat fever,
inflammation and pain. Administration of an ACEI and an
NSAID to the same animal may be considered, for ex-
ample, in cats suffering from both CKD and osteoarthritis.
In addition, ACEIs and NSAIDs may have additive efficacy
in certain cardiovascular diseases in which inflammation
is present, notably proteinuric CKD [2]. Additive effects of
ACEIs and NSAIDs in reducing proteinuria have been re-
ported in humans [3].
Negative pharmacodynamic interactions between ACEIs
and NSAIDs have been described in humans, however [4].
First, NSAIDs reduce the synthesis of vasodilatory prosta-
glandins and as a consequence may inhibit the systemic
anti-hypertensive efficacy of ACEIs [5]. Second, as a result
of reduction in vasodilatory prostaglandins, NSAIDs can
constrict the renal afferent arteriole leading to reduced
glomerular filtration rate (GFR) and in extreme cases
acute kidney injury (AKI). The risk of AKI with NSAIDs is
increased by dehydration or reduced blood pressure, for
example with general anaesthesia or administration of an
ACEI [6].
One of the principal mechanisms of action of ACEIs in
slowing the progression of CKD in humans is reduction in
glomerular capillary hypertension, mediated via selective
dilation of the efferent arterioles in the kidney [1]. As a re-
sult of reduced glomerular capillary pressure, ACEIs may
reduce GFR in patients with CKD. The benefit to risk ratio
of ACEIs in human CKD is positive, however, provided that
the reduction in GFR, usually evidenced by increased
plasma creatinine concentrations, is not excessive [7]. The
combination of vasoconstriction of the renal afferent arteri-
oles by an NSAID and dilation of the efferent arterioles by
an ACEI can however produce excessive reduction in GFR
potentially leading to AKI [3]. The risk of AKI is further
increased by concomitant use of diuretics which themselves
reduce blood flow to the kidney via intravascular volume
depletion. The danger of the combination of ACEIs, di-
uretics and NSAIDs in humans was described as a “triple
whammy” [8, 9].
To our knowledge, no controlled studies have been
reported on the combination of ACEIs and NSAIDs in
cats. In contrast to humans, a benefit of ACEIs in slow-
ing the progression of CKD has not been demonstrated
in cats, although the ACEI benazepril has been shown
to increase GFR while reducing glom
erular hypertension in an experimental model of renal
insufficiency [10] and to reduce proteinuria in clinical
cases of CKD [11]. No significant effect of the NSAID
robenacoxib on GFR was reported recently in healthy
cats administered furosemide [12]. The effect of the
combination of benazepril and robenacoxib on GFR in
cats is not known.
The objective of this study was to evaluate the effect
of benazepril, robenacoxib and their combination in
healthy cats. Two studies were conducted, the first with-
out and the second with concomitant administration of
the diuretic furosemide. The primary endpoint was the




Two studies (termed study 1 and study 2) were conducted
using similar study designs, except that in addition in study
2 furosemide was administered and plasma renin activity
(PRA) and plasma aldosterone concentration, urine vari-
ables including volume and specific gravity (USG), and
water intake were measured. Both studies followed a rando-
mised and parallel-group design comparing three treatment
groups (benazepril, robenacoxib and their combination) to
the control group (Table 1).
Studies 1 and 2 were performed respectively in com-
pliance with the registered permit numbers 2011_11_FR
and 2012_34E_FR approved by the Swiss cantonal ani-
mal welfare committee, and after approval of the proto-
col by the company Global Animal Welfare Unit. The
studies were designed to use the fewest number of ani-
mals possible while being consistent with the objectives.
The current state of scientific knowledge did not provide
acceptable alternatives, in vitro or otherwise, to the use
of live animals to accomplish the purpose of the studies.
The cat is a target species for the test items. Study 2 was
initiated only after positive tolerability results were ob-
tained from study 1. All cats were returned to the site’s
animal facilities upon completion of the study.
This manuscript was prepared in compliance with the
ARRIVE Guidelines Checklist for animal in vivo experi-
ments [13].
Table 1 Treatment groups
Group Treatment (mg/kg)
once daily orally
Study 1 Study 2
A None (placebo, control) Cohort 1 4 f 2 m & 2 f
Cohort 2 4 m 2 m & 2 f
B Benazepril (0.5–1.0) Cohort 1 4 f 2 m & 2 f
Cohort 2 4 m 2 m & 2 f
C Robenacoxib (1.0–2.4) Cohort 1 4 f 2 m & 2 f
Cohort 2 4 m 2 m & 2 f
D Benazepril (0.5–1.0) +
Robenacoxib (1.0–2.4)
Cohort 1 4 f 2 m & 2 f
Cohort 2 4 m 2 m & 2 f
f female, m male
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Study animals
A total of 48 unneutered European short-haired cats
(26 males plus 22 non-pregnant and nulliparous females)
were used, with 16 males and 16 females included in each
of the two studies. All cats had been bred specifically for
research purposes and were owned by the laboratory. A
total of 6 males and 10 females were used in both studies,
with a washout of 4 months. All cats were healthy and
had not received an ACEI or NSAID for at least 2 months
prior to each study.
Housing and management
The acclimatisation phase lasted approximately two weeks
and started on day -14 (study 1, Table 2) or -15 (study 2,
Table 3). During this phase, the cats were acclimatised to
their housing and management and were confirmed to be
healthy based on a physical examination, feed consump-
tion and results of clinical chemistry, haematology and
urinalyses.
The cats were housed in groups in a climate-controlled
building with artificial light from 6.00 to 18.00. The ani-
mals were placed in individual cages for up to 5 h daily to
record feed consumption, and in study 2 the cats were
also placed individually into cages two times for 24 h to
measure water consumption and urine volume, and to fa-
cilitate collection of urine samples.
Each cat was offered 40–70 g of dried pelleted feed
(Purina® Pro Plan Adult, Switzerland) once a day at 12.00
(±1 h), approximately 4 h after dosing with the test items.
On the days that blood samples were taken, cats were fed
approximately 4 h after dosing with the test items and after
the 4 h time point for iohexol determination. Drinking
water was supplied ad libitum.
Randomisation and blinding
The cats were assigned at random to one of four groups A,
B, C or D (4/gender/group, Table 1), while maintaining
homogeneous distribution of body weight where possible.
The randomisation was made by the statistician using SAS/
STAT® procedure plan [14]. Due to the experimental work-
load, the cats in both studies were divided into two cohorts
with the first day of dosing staggered by 1 day in study 1
and 7 days in study 2. In study 1, cohort 1 consisted of all
females and cohort 2 all males. In study 2, each cohort con-
sisted of 2 males and 2 females per group.
The study was not blinded. This was judged acceptable
since the main endpoints, including the primary end-
point, were objective.
Test items and furosemide
Benazepril was dosed once daily orally at a minimum
dose of 0.5 mg/kg (as the hydrochloride salt) with a
range of 0.5–1.0 mg/kg (Fortekor® Flavour 2.5 or 5 mg
tablets, Elanco Animal Health, Huningue, France). This
is the dosage of benazepril registered for the reduction
of proteinuria in cats with CKD in the EU [11].
Robenacoxib was dosed once daily orally at a mini-
mum dose of 1.0 mg/kg with a range of 1.0–2.4 mg/kg
(Onsior® 6 mg flavoured tablets, Elanco Animal Health,
Huningue, France). This is the dosage of robenacoxib
registered for the treatment of acute musculoskeletal
disorders in cats in the EU [15].
The seven day treatment time for the test items was
selected in order to reach steady state for benazeprilat
(steady state plasma concentrations within 2–3 days
[16]) and robenacoxib (terminal half-life 1–2 h in blood
and ~24 h in peripheral sites of inflammation [17, 18]).
In study 2, furosemide was administered at a target dose
of 0.5 ± 0.2 mg/kg twice daily (BID) by subcutaneous injec-
tion (Dimazon® Solution for injection, Merck Animal
Health, Kenilworth, NJ, USA). Injection was chosen as the
route of administration in order to minimise variability in
absorption. The manufacturer’s recommended dose of fur-
osemide is 5 mg/kg followed by maintenance at 1-2 mg/kg
every 6–8 h. However in a pilot study, furosemide doses of
1 or 2 mg/kg BID for 9 days to cats led to unacceptable
reduction in feed intake and body weight. In a second pilot
study, 0.5 furosemide mg/kg BID for 7 days produced a
significant diuretic effect and compared to 1 mg/kg BID
was better tolerated and produced numerically greater
stimulation of the renin-angiotensin-aldosterone-system
(RAAS), as assessed from PRA and aldosterone.
In order to avoid multiple administrations, benazepril and
robenacoxib were dosed together in combinations of whole
and part tablets in a single size 00 gelatin capsule. The con-
trol group received a placebo consisting of a single empty
size 00 gelatin capsule. All treatments were administered at
Table 2 Schedule of study 1
Category Cohort 1 study days Cohort 2 study days
Pre-treatment Post-treatment Pre-treatment Post-treatment
Administration of test items 0 to 6 1 to 7
Haematology, coagulation, clinical chemistry −14 2, 9 −14 3, 10
Body weight −15, −8, −1 6 −15, −7, −1 7
Feed consumption −15 to −8, −7 to −1 0 to 6, 7 to 10 −15 to −8, −7 to 0 1 to 7, 8 to 10
Iohexol concentration (0, 2, 3 & 4 h) −8 6 −7 7
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8.00 ± 1 h (in study 2 furosemide was administered at
8.00 ± 1 h and 20.00 ± 2 h). After dosing, 2.5 mL of
water was administered via a syringe to facilitate pas-
sage of the capsules into the stomach, and the cats were
observed for several minutes to ensure that the capsules
had been swallowed.
Doses were determined using the body weight measured
on day -1, or day 5 for cohort 2 in study 2 (Table 3). Except
for unplanned medical treatments, additional medications
were prohibited during the studies.
Endpoints
The primary endpoint of the study was the GFR, which
was estimated from the plasma clearance of iohexol
(CLioh).
Secondary endpoints included general clinical monitoring
(body weight, clinical examination, feed consumption,
clinical chemistry, coagulation and haematology). In study
2, additional secondary endpoints were PRA and plasma
aldosterone concentration, water intake, urine volume and
USG, and fractional excretions of potassium and sodium.
Clinical monitoring
Cats were checked at least once daily. A detailed clinical
examination was made once during the acclimatisation
phase, and then again 96 h after the first dose of the test
items and the day following the last dosing.
Cats were weighed in the morning before feeding at
least three times in the baseline period and again at the
end of the study (Tables 2 and 3). Daily feed consumption
was determined as the difference between rations offered
and remaining uneaten after approximately 4 h.
Blood samples for clinical pathology (standard haema-
tology, coagulation and plasma clinical chemistry variables)
were taken from a cephalic or jugular vein, after feed was
removed for at least 12 h, once during the acclimatisation
phase (for animal selection and as baseline), once during
the treatment phase and in study 1 again after the end of
treatment (Tables 2 and 3).
Glomerular filtration rate (GFR)
The GFR was estimated from the CLioh after intravenous
(IV) administration of iohexol (Accupaque® 350, GE
Healthcare Buchler GmbH & Co., Braunschweig,
Germany). This was performed once during the acclima-
tisation phase prior to administration of the test item(s)
(day -8 or -7) and again after the last treatment.
Cats had free access to water but feed was withheld for
at least 12 h before IV administration of iohexol. A target
dose of 90 mg of iodine/kg iohexol was administered via
an IV catheter placed in a cephalic vein followed by flush-
ing with physiological saline solution. Actual mean (range)
doses administered were 90.0 (86.4.2–93.8) iodine/kg in
study 1 and 88.9 (81.8–94.3) iodine/kg in study 2. Blood
was sampled from a jugular or antebrachial vein (i.e. not a
vein used for iohexol administration) in 1.2 mL heparin
tubes before and 2, 3 and 4 h after administration of
iohexol. Samples were stored on ice until centrifuged at
approximately 3,000 g for 15 min at 4 °C. Once centri-
fuged, plasma was collected and stored at -20 °C before
analysis.
Due to breakdown of equipment between studies,
plasma iohexol concentrations were analysed using two
different methods in studies 1 and 2. Both methods were
validated in cat plasma in terms of selectivity, linearity,
repeatability, reproducibility and stability according to
the document “Guidance for Industry: Bioanalytical
Method Validation” (U.S. Department of Health and Hu-
man Services et al., 2001, http://www.labcompliance.com/
info/links/methods/guidelines.aspx).
In study 1, the endo- and exo-iohexol isomers were quan-
tified separately. Analyses were performed on a high per-
formance liquid chromatography system (Hewlett Packard
1100, Palo Alto, CA, USA) coupled with an ultraviolet
Table 3 Schedule of study 2
Category Cohort 1 study days Cohort 2 study days
Pre-treatment Post-treatment Pre-treatment Post-treatment
Administration of test items and furosemidea 0 to 6 7 to 13
Haematology, coagulation −15 5 −15 12
Clinical chemistry −15, −8 5 −15, −8 12
Urinalysis and water consumption −14, −7b 6 −14, −7b 13
Body weight −16, −13, −9, −6, −1 7 −16, −13, −9, −6, −1, 5 14
Feed consumption −16 to −1 0 to 6 −16 to 6 7 to 14
Iohexol concentration −8 (0, 2, 3 & 4 h) 6 (0, 2, 3 & 4 h) −7 (0, 2, 3 & 4 h) 13 (0, 2, 3 & 4 h)
Plasma renin activity and aldosterone concentration 0c 6 (0 h) 6 (2, 6, 12 & 24 h) 7c 13 (0 h) 13 (2, 6, 12 & 24 h)
h hour
aFurosemide was administered subcutaneously twice daily on days 0 to 5 (cohort 1) or 7 to 12 (cohort 2) and then as a single dose on the morning of day 6
(cohort 1) or 13 (cohort 2)
bUrinalysis at day −7 only if no sample was taken at day −14
cFor plasma renin activity and plasma aldosterone, the day 0/7 value not used in the analysis
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detector (Hewlett Packard 1050). The method was linear
over the calibration ranges 1 to 80 μg/mL and 2 to
320 μg/mL for endo- and exo-iohexol respectively. Intra-
day and inter-day precisions were lower than 9 % for both
isomers. The accuracy varied from 98 to 102 %. The lower
limit of quantification (LLOQ) was 1 μg/mL with precision
8 % and accuracy 99 % for endo-iohexol, and 2 μg/mL with
precision 10 % and accuracy 109 % for exo-iohexol.
In study 2, total plasma iohexol concentrations were
measured using an ultra-high performance liquid chroma-
tography system (Acquity UPLC, Waters, Milford, MA,
USA) coupled with a triple quadrupole mass spectrometer
(Xevo, Waters). The method was validated with a calibra-
tion curve ranging from 5 to 400 μg/mL. Intra-day and in-
ter-day precisions were respectively lower than 11 and
12 %. The accuracy varied from 87 to 102 %. The
LLOQ was 5 μg/mL with a precision of 7 % and an ac-
curacy of 91 %.
The CLioh was calculated using the methods described
by Laroute et al., [19]. In brief, it was first checked that the
pre-administration concentrations of iohexol in plasma
were below the LLOQ. Next, a log-linear regression of total
iohexol concentration versus time was calculated using:
log concentration ¼ α þ ðβ x timeÞ
The area under the curve (AUC) is then:
AUC ¼ exp αð Þ= ‐βð Þ
Clearance (CL) was calculated as:
CL ¼ dose=AUC
The CL was calculated relative to body weight (BWT)
and relative to body surface area (BSA), the latter being
estimated by:
BSA m2
   ¼ 0:00101  BWT g½ ð Þ0:71
Urine variables
In study 2, the cats were placed in cages with specialised
litter trays for 24 h on days -14 or -7 and 6 or 13. Water
consumption and urine volume were measured and urine
samples collected.
The total volume of water consumed over 24 h was cal-
culated from the difference in volume of water provided
and remaining in bowls which were suspended above the
floor. The volume was checked repeatedly during the day.
Urine was collected from litter trays by using Catrine
Pearl Cat Litter® (Kruuse, Langeskov, Denmark).
Urine samples were stored at below -70 °C before ana-
lysis for creatinine, potassium and sodium concentrations
and USG. The fractional excretions of potassium (FEK)
and sodium (FENa) were calculated according to the fol-
lowing formulae:
K fractional excretion %ð Þ ¼ Urine K x Plasma Creatinine
Plasma K x Urine Creatinine
Na fractional excretion %ð Þ ¼ Urine Na x Plasma Creatinine
Plasma Na x Urine Creatinine
Plasma renin activity (PRA) and aldosterone concentration
In study 2, pre-treatment and on the last day of dosing,
approximately 1.2 mL of blood was collected in the mor-
ning before administration of furosemide and test items
(pre-dose) and 2, 6, 12 and 24 h later (post-dose). Blood
was collected into pre-cooled tubes containing K3 EDTA
and aprotinin (500 KIU/mL of blood) and kept on ice
until centrifugation at approximately 3,000 g for 15 min
at 4 °C. The plasma was collected and stored below -70 °C
until analysis. Plasma angiotensin-1 concentrations were
measured using an enzyme immuno-assay (Penisula Labs,
San Carlos, CA, USA). The PRA was calculated by
comparing the concentration of angiotensin-1 obtained
after incubation of the samples at +4 °C (absence of
renin activity) and +37 °C (presence of renin activity).
The angiotensin-1 assay was validated, over the concen-
tration range 30 to 700 pg/mL. Quality control samples
at 60, 145 and 500 pg/mL were analysed in each run;
the accuracy was within the defined acceptable range of
75–125 % for all 48 samples, with a mean (coefficient
of variation (CV%)) accuracy of 96.7 (7.7 %).
Aldosterone was determined in plasma using a Symbiosis
liquid chromatography-mass spectrometry system (online
SPE, Spark Holland, Emmen, Netherlands). Concentrations
of aldosterone are low in urine of cats and therefore
plasma concentrations are more relevant clinically [20].
The assay was validated over the concentration range 0.05
to 2.0 ng/mL. Quality control samples at 0.12, 0.6 and
1.8 ng/mL were analysed in each run; the accuracy was
within the defined acceptable range of 75–125 % for all 27
samples, with a mean (CV%) accuracy 96.6 (5.7 %).
Statistical analysis
The software SAS®, Version 9.2 or higher, was used for all
analyses [14]. Data are presented as mean (± SD) or range.
The experimental unit was results from each individual
cat. Two tailed P values less than 0.05 were defined as sig-
nificant with no correction for multiple analyses, in order
not to inflate the type II error.
Variables that were analysed only once post-treatment,
including GFR, were analysed using analysis of covariance
(ANCOVA) with the pre-treatment value as covariate and
sex, treatment, and “treatment by sex” interaction as ef-
fects (Tables 4 and 6). Various data transformations were
attempted and the adequacy of each statistical model was
assessed by evaluation of the normality of the residuals
(Shapiro-Wilk test, SAS® procedure univariate). In all
cases, no or a log transformation was selected.
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Variables that were measured pre-treatment and mul-
tiple times post-treatment were analysed using repeated
measures analysis of covariance (RMANCOVA) (Table 7).
The pre-treatment value was the covariate and effects
were sex, treatment, time and “treatment by sex” and
“treatment by time” interactions.
In the event that the P value was less than 0.1 for
treatment or the “treatment by sex” or “treatment by time”
interactions, individual groups were compared by linear
contrasts with P < 0.05 defined as significant.




The 32 cats were aged 8 months to 7 years with body-
weight 2.5–6 kg at baseline. Groups were well matched at
baseline. The mean (range) doses of the test items in mg/
kg administered orally once daily alone and in combination
were respectively 0.69 (0.51–0.88) and 0.70 (0.51–0.98) for
benazepril hydrochloride and 1.67 (1.16–2.27) and 1.67
(1.23–2.36) for robenacoxib.
Clinical monitoring
All test items were well tolerated. One isolated event
of bloody loose stools on day 7 was observed in one
cat in group B (benazepril) but was not considered to
be caused by the test item. No other clinical signs were
reported.
There was no significant (P > 0.1) treatment effect or
“treatment by time” or “treatment by sex” interactions
for feed intake or for relevant haematology, coagula-
tion or clinical chemistry variables (data not shown).
Certain variables showed significant (P < 0.05) changes
from baseline. These included the red cell variables
(cell count, haemoglobin and haematocrit) which de-
creased in all four groups. For coagulation variables,
fibrinogen decreased in group B (benazepril) and the
activated partial thromoplastin time increased in group B
(benazepril) and group D (benazepril plus robenacoxib).
For clinical chemistry variables, plasma albumin and
calcium decreased and chloride increased in all four
groups. There were also increases in plasma potassium
(C and D) and sodium (A, B and D), and decreases in
aspartate amino-transferase (A and B), phosphorus (A,
B and C), total protein (B and D) and urea nitrogen (B
and C).
There was a significant “treatment by sex” interaction
for body weight, and significant differences between
groups in the post-hoc comparisons (Table 4). Differences
in change from baseline were small however: B -0.06 kg
versus A in males; A -0.08 versus C in females; D -0.05
(all) and -0.08 (females) versus C.
Glomerular filtration rate (GFR)
The GFR was assessed from the CLioh. There was low
variability in plasma iohexol concentrations (Fig. 1). Simi-
lar results were obtained in both studies with CLioh
expressed per BWT or BSA. Final conclusions were made
using BSA since P values for the normality of the data
were higher in both studies with CLioh expressed per BSA
(Tables 4 and 6).
For CLioh expressed both by BWT or BSA, there were
highly significant effects of treatment, sex, “treatment by
sex” and baseline in study 1 (Fig. 1, Table 4). In the post-
hoc analyses, iohexol clearance was significantly greater
in group D (benazepril and robenacoxib) versus the
other groups (A, B and C) in all cats and in females. In
addition for the BSA endpoint, the clearance was signifi-
cantly higher in group B (benazepril) compared to the
control (A) in females and significance was approached
(P = 0.051) for males.
The iohexol clearance was highly significantly (P <
0.0001) increased compared to baseline in group D
(benazepril and robenacoxib) for both BWT and BSA
endpoints (all cats and females). The mean change from
baseline in CLioh expressed per BSA was: -9.5 %,
+12.8 %, +1.3 % and +36.1 % respectively in groups A,
B, C and D.
Table 4 Results of statistical analyses for selected variables in study 1 analysed by ANCOVA
Variable Transformation P values in ANCOVA P value for normality P < 0.05 in post-hoc tests*
Treatment Sex Treatment by sex Baseline
Iohexol clearance
per BWT
None 0.0030* 0.0002* 0.0017* 0.0003* 0.1957 A, B & C < D (all & f)
Iohexol clearance
per BSA
None 0.0036* 0.0005* 0.0013* 0.0005* 0.6001 A, B & C < D (all & f), A < B (f)
Body weight None 0.1823 0.3007 0.0303* < 0.0001* 0.4012 B < A (m), A < C (f), D < C (all & f)
Only results of variables with a significant (P < 0.1) treatment or “treatment by sex” effect are shown. For sex, baseline, normality and post-hoc comparisons,
P < 0.05 was defined as significant
BWT body weight, BSA body surface area, f female, m male
*Results were primarily interpreted from the effect with the P value shown in bold
King et al. BMC Veterinary Research  (2016) 12:124 Page 6 of 15
Study 2
The 32 cats were aged 1–8 years with bodyweight 2.8–
7.6 kg at baseline. Groups were well matched at baseline.
The mean (range) doses of the test items in mg/kg ad-
ministered once orally daily alone and in combination
were respectively 0.72 (0.51–0.88) and 0.79 (0.58–0.98)
for benazepril hydrochloride, and 1.50 (1.02–2.14) and 1.49
(1.05–2.22) for robenacoxib. The mean (range) dose of
furosemide was 0.55 (0.50–0.65) mg/kg BID by subcutane-
ous injection. The furosemide had the desired diuretic
effect, producing a marked increase in urine volume
(mean +113 %) associated with dehydration, reduced
GFR and increase in plasma creatinine concentrations,
and activation of the RAAS evidenced from increased
PRA and aldosterone concentrations.
P values for the primary endpoint and selected (statisti-
cally significant) secondary variables are shown for change
from baseline (Table 5), ANCOVA (Table 6) and RMAN-
COVA (Table 7) analyses.
Clinical monitoring
The test items were tolerated well. Body weight was sig-
nificantly lower in the control group (A) during treatment
compared to the robenacoxib group (C) (Table 6). Inci-
dents of diarrhoea in 4 cats and vomiting in one cat were
reported in the pre-test phase but not during dosing with
Fig. 1 Plasma clearance of iohexol, standardised to baseline body weight (BSA), as an index of glomerular filtration rate in study 1. Upper: Scatter Plots.
Data are shown as solid (males) and dotted (female) lines. Lower: Mean (SD) for all cats, and separately for males and females. Control (A) –o-; Benazepril
(B) ; Robenacoxib (C) ; Benazepril + Robenacoxib (D)
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the test items. Skin lesions, attributed to the repeated sub-
cutaneous injection of furosemide or clipping of hair for
blood sampling, were observed in one cat in group A and
two cats in group D.
Clinical signs attributed to the furosemide included dehy-
dration in 12 animals (4 in group A, 3 in B, 1 in C and 4 in
D). Reduced appetite was observed in most cats during
furosemide administration and this was reported as inappe-
tence on one or more days for 7 cats (4 in group A, 1 in B
and 2 in D). One cat (control group A) was withdrawn from
the study due to decreased appetite plus dehydration and
prostration.
In the control group (A) there were significant increases
(% change) from baseline in: red cell count (+18.0 %),
Table 5 P values for change from baseline for selected variables in study 2







Group D: Benazepril +
Robenacoxib
Iohexol clearance per BWT M 0.0068 D 0.0003 D < 0.0001 D 0.0002 D
F 0.0033 D 0.9475 0.0248 D 0.0003 D
Both 0.0001 D 0.0052 D < 0.0001 D < 0.0001 D
Iohexol clearance per BSA M 0.0365 D 0.0006 D < 0.0001 D 0.0002 D
F 0.0005 D 0.4843 0.0030 D < 0.0001 D
Both 0.0002 D 0.0024 D < 0.0001 D < 0.0001 D
Plasma renin activity Day 6/13 + 2 h < 0.0001 I < 0.0001 I 0.0012 D < 0.0001 I
Day 6/13 + 6 h 0.0002 I < 0.0001 I 0.0166 D 0.0002 I
Day 6/13 + 12 h 0.1776 0.0141 I 0.0010 D 0.6073
Day 6/13 + 24 h 0.0284 I 0.8368 < 0.0001 D 0.0522 (D)
Plasma aldosterone Day 6/13 + 2 h 0.0211 I 0.0012 D 0.5563 0.0005 D
Day 6/13 + 6 h 0.3873 0.0914 (D) 0.9468 0.0022 D
Day 6/13 + 12 h 0.3893 0.1708 0.2046 0.0262 D
Day 6/13 + 24 h 0.5757 0.0020 D 0.0002 D 0.0054 D
Red blood cell count < 0.0001 I 0.0093 I 0.0816 (I) 0.0758 (I)
Haematocrit 0.0004 I 0.0109 I 0.1306 0.0771 (I)
Haemoglobin 0.0001 I 0.0077 I 0.2113 0.0298 I
Prothrombin time 0.0008 D 0.0014 D 0.0238 D < 0.0001 D
Activated partial thromboplastin time 0.0026 D 0.0077 D 0.2387 0.0515 (D)
Albumin < 0.0001 I 0.0002 I 0.1479 0.0595 (I)
Alkaline phosphatase 0.0121 D 0.0001 D 0.0429 D < 0.0001 D
Aspartate aminotransferase 0.0009 I 0.0232 I 0.1196 0.0276 I
Creatinine < 0.0001 I < 0.0001 I < 0.0001 I < 0.0001 I
Total protein 0.0004 I 0.0510 (I) 0.9288 0.7448
Urea nitrogen < 0.0001 I < 0.0001 I < 0.0001 I < 0.0001 I
Calcium 0.0004 I 0.0005 I 0.0045 I 0.2532
Chloride < 0.0001 D < 0.0001 D < 0.0001 D < 0.0001 D
Magnesium < 0.0001 I 0.0003 I 0.0033 I 0.0022 I
Potassium 0.0010 D < 0.0001 D 0.0081 D < 0.0001 D
Sodium < 0.0001 D < 0.0001 D 0.0188 D < 0.0001 D
Water consumption 0.0002 I < 0.0001 I < 0.0001 I < 0.0001 I
Urine volume 0.0025 I < 0.0001 I 0.0019 I 0.0003 I
Urine specific gravity < 0.0001 D < 0.0001 D < 0.0001 D < 0.0001 D
Fractional excretion potassium 0.0029 I < 0.0001 I 0.0009 I < 0.0001 I
Only variables with at least one significant (P < 0.05) change from baseline are shown
BWT body weight, BSA body surface area, F female, M male, h hour
D decrease, I increase (in bold for P < 0.05). Non-bold P values and D or I in brackets for P < 0.1
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haematocrit (+19.7 %) and haemoglobin (+20.4 %); plasma
concentrations of albumin (+0.88 %), creatinine (+39.1 %),
total protein (+12.0 %) and urea nitrogen (+15.2 %); water
consumption (+73.9 %), urine volume (+113.1 %) and FEk
(+75.2 %) (Table 5). There were significant decreases in:
prothrombin (-1.8 %) and activated partial thromboplastin
time (-4.8 %); plasma concentrations of chloride (-14.9 %),
potassium (-10.4 %) and sodium (-4.7 %); and in USG
(-6.1 %).
For the variables listed above, there was a significant
treatment effect for albumin, total protein, chloride and
sodium (Table 6). In the post-hoc comparisons, albumin
and total protein were significantly lower in groups C
and D versus the control (A), while chloride and sodium
were significantly higher in group C versus A.
There was a significant “treatment by sex” interaction
for USG, and in the post-hoc comparisons female cats
had lower USG in group B (benazepril) compared to the
control (A).
Glomerular filtration rate
Similar results were obtained with CLioh expressed per
BWT or BSA, with final conclusions made using BSA
since the P value for normality was higher (Table 6). The
CLioh decreased significantly from baseline in all groups
(Fig. 2, Table 5), attributed to the effect of furosemide.
For CLioh expressed per BSA, there were significant
treatment and “treatment by sex” effects. In the post-hoc
comparisons, CLioh was significantly higher in the bena-
zepril group (B) compared to the control (A, females
only) and benazepril plus robenacoxib groups (D, fe-
males and all cats). The CLioh was significantly higher
in the control group (A) compared to robenacoxib (C,
males only).
The mean change from baseline in CLioh expressed per
BSA was: -20.4 %, -19.9 %, -31.6 % and -33.7 % respectively
in groups A, B, C and D.
Plasma renin activity (PRA) and aldosterone
In the control group (A) there were significant increases
from baseline in PRA (at 2, 6 and 24 h after dosing) and
plasma aldosterone concentrations (at 2 h) (Figs. 3 and 4,
Table 5). At peak effect (2 h), mean values were increased
by +1083 % for PRA and by +519 % for aldosterone.
There were significant treatment and “treatment by
time” effects for both PRA and aldosterone (Table 7). In
the post-hoc analyses for PRA, values were significantly
lower in group C versus groups A and D at all time points,
and in group D compared to the control group A at 24 h.
In the post-hoc analyses for aldosterone, values were
significantly lower at one or more time points in groups B
(2 h), C (24 h) and D (2, 6 and 12 h) compared to the con-
trol group A. Values were also significantly lower in group
D compared to C at 2 and 6 h. Examination of the mean
values indicates, however, that all three treatment groups
(B, C and D) were associated with approximately equal
inhibition of the increase in plasma aldosterone induced
by furosemide (Fig. 4).
Discussion
In humans concomitant administration of ACEIs and
NSAIDs can potentially lead to adverse events, notably
reduction in GFR and the occurrence of AKI. This risk
is worsened by concomitant administration of diuretics,
described as a “triple whammy” [8, 9]. In this study in
healthy cats, no reduction in GFR was observed with the
combination of benazepril and robenacoxib, with and
without concomitant administration of the loop diuretic
furosemide. Similar findings were reported recently in
Table 6 P values for selected variables in study 2 analysed by ANCOVA
Variable Transformation P values in ANCOVA P value for
normality
P < 0.05 in post-hoc tests*
Treatment Sex Treatment by sex Baseline
Iohexol clearance per BWT None 0.0726 0.0534* 0.0451* 0.4365 0.2246 A < B (f), C < A (m), D < B (f & all)
Iohexol clearance per
BSA
None 0.0435* 0.2698 0.0300* 0.5357 0.6285 A < B (f), C < A (m), D < B (f & all)
Body weight None 0.0865* 0.2900 0.1127 < 0.0001* 0.4772 A < C
Albumin None 0.0066* 0.3807 0.6866 0.1354 0.3174 C & D < A
Total protein Log 0.0276* 0.7737 0.4227 0.0055* 0.0246* C & D < A
Chloride None 0.0245* 0.9598 0.5484 0.2485 0.8120 A < C
Sodium None 0.0411* 0.3906 0.9749 0.8905 0.4006 A & D < C
Urine specific gravity None 0.1205 0.4124 0.0914* 0.0544* 0.5961 B < A (f)
Only results of variables with a significant (P < 0.1) treatment or “treatment by sex” effect are shown. For sex, baseline, normality and post-hoc comparisons,
P < 0.05 was defined as significant
BWT body weight, BSA body surface area, f female, m male
*Results were primarily interpreted from the effect with the P value shown in bold
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Table 7 P values for selected variables in study 2 analysed by RMANCOVA
Variable Transformation P values in RMANCOVA P value for
normality
P < 0.05 in post-hoc tests*





Log < 0.0001* < 0.0001* 0.0019* 0.0048* 0.0322 C < A & D (2, 6, 12 & 24 h), D < A (24 h)
Plasma aldosterone Log 0.0275* 0.0004 * 0.0128* < 0.0001* 0.1342 B < A (2 h), C < A (24 h), D < A (2, 6 & 12 h),
D < C (2 & 6 h)
Only results of variables with a significant (P < 0.1) treatment or “treatment by time” effect are shown. For time, baseline, normality and post-hoc comparisons,
P < 0.05 was defined as significant. There were no significant sex or “sex by treatment” interactions for these variables (data not shown)
BWT body weight, BSA body surface area, h hour
*Results were primarily interpreted from the effect with the P value shown in bold
Fig. 2 Plasma clearance of iohexol, standardised to baseline body weight (BSA), as an index of glomerular filtration rate in study 2. Upper: Scatter Plots.
Data are shown as solid (males) and dotted (female) lines. Lower: Mean (SD) for all cats, and separately for males and females. Control (A) –o-; Benazepril
(B) ; Robenacoxib (C) ; Benazepril + Robenacoxib (D)
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Fig. 3 Plasma renin activity (PRA) in study 2. Data are mean (SD) and scatter plots. Test items (benazepril and/or robenacoxib) plus furosemide
were administered at time 0 h. D = day. Control (A) –o-; Benazepril (B) ; Robenacoxib (C) ; Benazepril + Robenacoxib (D)
Fig. 4 Plasma aldosterone concentration in study 2. Data are mean (SD) and scatter plots. Test items (benazepril and/or robenacoxib) plus furosemide
were administered at time 0 h. D = day. Control (A) –o-; Benazepril (B) ; Robenacoxib (C) ; Benazepril + Robenacoxib (D)
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dogs [21]. The dose of furosemide administered (in
study 2) was 0.5 mg/kg BID by subcutaneous injection.
This is lower than the dose range of 1–5 mg/kg recom-
mended by the manufacturer, but in pilot studies doses
of 1 mg/kg BID and higher produced unacceptable loss
of appetite. At the chosen dose, furosemide had the de-
sired diuretic action in study 2, leading in the control
group to a significant increase (% change from baseline) in
urine volume (+113.1 %) and estimated water consump-
tion (+73.9 %), induced dehydration (haematocrit +19.7 %,
total plasma protein +12.0 %), reduced USG (-6.1 %)
and renal function (plasma creatinine +39.1 %, GFR
-20.4 %), and decreased prothrombin (-1.8 %) and acti-
vated partial thromboplastin (-4.8 %) times. The fur-
osemide also led to activation of the RAAS, evidenced
by significant increases in PRA and plasma aldosterone
concentrations (respectively +1083 % and +519 % at peak
effect). In addition, 4 of 12 cats in the control group re-
ceiving furosemide had reported inappetence and one cat
had to be withdrawn from the study due to decreased ap-
petite plus dehydration. The dose of furosemide was
therefore sufficient to induce the necessary pharmaco-
logical effects needed for this study to be relevant clinic-
ally, and was the highest that could be accepted from an
animal welfare perspective. Furosemide reduced GFR
significantly and by a mean of 20.4 %. This is a known
effect of diuretics, mediated via reduction in perfusion
pressure. The diuretic action of furosemide, but with
no reduction in GFR, has been demonstrated previously
in cats [22].
In this investigation benazepril had no significant effect
on GFR compared to the control group in all cats, although
GFR was increased in female cats only in both studies 1
and 2. The PRA was increased compared to baseline by a
similar extent in the control (A) and benazepril (B) groups
in study 2. Increased PRA is a standard effect of ACEIs
mediated by reduced synthesis of angiotensin-2 reducing
the negative feedback of angiotensin-2 on renin release.
The fact that benazepril did not increase PRA, an index of
RAAS activation, more than that induced by furosemide
alone suggests that the increase in PRA induced by the
0.5 mg/kg BID furosemide dose was already maximal. This
conclusion is supported by results from the pilot study in
which a dose of 1.0 mg/kg furosemide BID did not increase
PRA more than 0.5 mg/kg BID. Finally, benazepril signifi-
cantly inhibited the increase in plasma aldosterone induced
by furosemide. Inhibition of aldosterone synthesis, second-
ary to reduced synthesis of angiotensin-2, is a known action
of ACEIs including in cats [23].
The effects observed with benazepril, with inhibition
of the RAAS and reduction of plasma aldosterone
concentrations, are consistent with its demonstrated
action in reducing proteinuria in cats with CKD [11].
As noted in the introduction, ACEIs as a group have the
potential to reduce GFR in (human) patients with heart or
kidney disease [7]. In cats with CKD however, no signifi-
cant increase in plasma creatinine concentrations was ob-
served with benazepril compared to placebo, even at the
start of treatment [11], consistent with the finding in this
study that benazepril did not reduce GFR. Previously
Brown et al., also reported that benazepril increased GFR
in cats with nephrectomy-induced chronic renal insuffi-
ciency [10].
Administration of robenacoxib without benazepril pro-
duced no consistent effects on GFR. The change from
baseline in GFR in the robenacoxib versus the control
group was respectively +1.3 % versus -9.5 % in study 1,
and -31.6 % versus -20.4 % in study 2 (with furosemide).
Differences were significantly different for males in study 2.
No significant effects of robenacoxib on GFR were re-
ported previously at a high dose (30 mg/kg) in rats [24] or
at a clinically relevant dose (2 mg/kg SID or BID orally) in
cats [12].
Limited studies on the effect of other NSAIDs on GFR in
cats are available. Meloxicam was reported not to change
GFR in healthy euvolaemic cats with reduced renal mass
[25] or fed a sodium deficient diet [26]. In addition no evi-
dence of deleterious effects on renal function, assessed from
plasma creatinine and urea concentrations and lack of ad-
verse events, was reported from field studies in cats receiv-
ing carprofen [27, 28], meloxicam [28–30] or robenacoxib
[31, 32]. However, in one retrospective study, 48 cases of
acute renal failure were reported in cats and 21 of these
cases were attributed to the NSAIDs nimesulide (16), tolfe-
namic acid (3) and ketoprofen (2) [33].
Robenacoxib administered alone significantly inhibited
the increase in both PRA and plasma aldosterone con-
centrations induced by furosemide. Similar results were
reported previously with robenacoxib in dogs [21] and
other NSAIDs in rats and humans [34, 35]. However no
effect of robenacoxib on PRA or aldosterone compared
to placebo was reported recently in healthy cats admin-
istered furosemide [12].
Many of the renal effects of furosemide are mediated by
prostaglandins, and it has been shown in rats and humans
that certain NSAIDs inhibit the diuretic, natriuretic and
chloruretic effects of furosemide via inhibition of the re-
absorption of sodium and chloride in the loop of Henle [35].
There is only weak evidence from this study that robena-
coxib inhibited the diuretic action of furosemide; the signifi-
cant increases from baseline in plasma albumin and total
protein concentrations induced by furosemide were signifi-
cantly attenuated by robenacoxib and the combination of
benazepril and robenacoxib, consistent with less dehydra-
tion. In addition, robenacoxib alone inhibited the reduction
in body weight (which correlated with reduced feed con-
sumption) and plasma sodium and chloride concentrations
induced by furosemide. However there were no significant
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or numerically visible differences between robenacoxib and
placebo treated cats for other relevant variables including
water consumption, urine volume and USG.
The principal objective of this study was to investigate
the tolerability of the combination of benazepril and
robenacoxib, notably with concomitant administration
of furosemide. The triple administration of an ACEI, di-
uretic and an NSAID increases markedly the risk of AKI
in humans [8, 9]. In this investigation, the combination
of benazepril and robenacoxib was tolerated well and
had no significant negative effects on GFR compared to
the control group. In study 1, in fact, the combination of
benazepril and robenacoxib was associated with a sig-
nificant increase in GFR (+36.1 %) from baseline, com-
pared to a 9.5 % decrease in the control. In study 2, with
furosemide, the GFR was significantly lower in the bena-
zepril and robenacoxib combination group compared to
the benazepril group, but was not significantly different
from the control. Therefore the results do not preclude
the possibility that GFR might decline if robenacoxib
was administered to a suspectible (e.g. dehydrated) cat
which was previously stable with benazepril treatment.
The combination of benazepril and robenacoxib sig-
nificantly inhibited plasma aldosterone concentrations
compared to the control group, with mean values nu-
merically similar to the benazepril alone group but with
statistical significance at more time points (2, 6 and 12
versus 2 h). These results support the rationale for inves-
tigation of co-administration of benazepril and robena-
coxib in certain diseases in cats e.g. proteinuric CKD.
Aldosterone is a key mediator contributing to the pro-
gression of CHF and CKD in humans [36, 37]. Although
higher aldosterone concentrations were detected in cats
with hypertension [38], we are not aware of data reliably
demonstrating a link between elevated aldosterone con-
centrations and a poor prognosis in cats. Additive effects
of ACEIs and NSAIDs in reducing proteinuria have been
described in humans [2, 3].
The principal limitations of the study are listed below.
First, healthy and relatively young cats were studied
and the results cannot therefore be simply generalised to
cats with diseases such as CKD and osteoarthritis. For
example, the residence time of robenacoxib in tissues is
markedly prolonged by the presence of inflammation
[18] and therefore its duration of action may also be lon-
ger in the feline kidney if inflammation is present as
compared to the healthy animals used in this study. In
addition, the effect of the test items, including on GFR,
might be different in the presence of diseases.
Second, the main endpoints in this study were orien-
tated to safety, including GFR to assess the risk of AKI.
We did not measure blood pressure, and therefore did
not test for a possible interaction of robenacoxib with
the anti-hypertensive efficacy of benazepril.
Third, GFR was assessed 2–4 h after dosing with the test
items i.e. close to the peak concentrations of plasma bena-
zeprilat (≤2 h) and blood robenacoxib (0.5 h) [16, 17]. The
observed effects of benazepril and robenacoxib on GFR
therefore presumably represent maximal or close to max-
imal actions, and different (probably lesser) effects might
occur at other times (4–24 h) of the dosing interval.
Fourth, the cats were fed a standard diet and were dosed
with the test items in the morning at approximately 8.00.
Chronological differences and marked effects of feeding
on the RAAS have been reported in dogs [39], and there-
fore different results might be obtained with other diets or
different timings of feeding or dosing.
Fifth, sex and “sex by treatment” interactions were sig-
nificant for several variables in both studies. The fre-
quency of these interactions was greater in study 2,
therefore the weakness in study design in study 1 (all fe-
males were included in cohort 1 and all males in cohort 2)
did not appear to have a relevant impact on the results.
We are not aware of previous reports of genuine gender
differences in the effects of ACEIs or NSAIDs on GFR in
other species. No sex differences were reported previously
in the pharmacokinetics or pharmacodynamics of benaze-
pril [16, 40, 41] or robenacoxib [17, 42] in cats. Therefore
we suspect that the observed differences between genders,
in addition to isolated events of statistical significance for
some chemistry and haematology variables, may be type I
errors associated with the multiple statistical analyses with
no correction of the alpha value, rather than being genuine
biological effects.
Last, the results of this study cannot be simply extrapo-
lated to other ACEIs and NSAIDs since the pharmacology
of individual agents differ. Of specific relevance to this
study is fact that the active metabolite of benazepril, bena-
zeprilat, is excreted mainly (~85 %) via the biliary rather
than renal (~15 %) route in cats [41], and therefore its
clearance is maintained even in the presence of moder-
ate renal insufficiency [40]. Similar conclusions might
therefore not be obtained for other ACEIs which are
mainly or exclusively renally excreted. In addition robe-
nacoxib has a short residence time in the central com-
partment [17, 18], and therefore is assumed to have
short duration pharmacodynamic actions in the healthy
kidney. Similar conclusions might therefore not be ob-
tained with NSAIDs with longer half-lives or which are
not cyclo-oxygenase (COX)-2 selective. Robenacoxib is
a highly selective inhibitor of COX-2 [42], and there is
some evidence in humans that the risk of AKI may be
lower with selective COX-2 inhibitors compared to
non-selective NSAIDs [43].
Conclusions
The combined administration of benazepril and robena-
coxib was well tolerated, and either increased or had a
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neutral effect on GFR compared to the control group in
healthy cats without or with concomitant furosemide.
The combination of benazepril and robenacoxib reduced
plasma aldosterone concentrations increased by furosemide
and therefore might be beneficial in cats with certain dis-
eases, notably proteinuric CKD. It is recommended to test
the efficacy and clinical safety of combined administration
of benazepril and robenacoxib in cats in field studies.
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